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expanded services and mandating quality. Studies show that wellness programs are 
growing in number and in various sizes, services, and incentives resulting in a signif-
icant to non-significant return-on-investment (ROI). Few employers have measured 
the ROI and even fewer their health outcomes. However, successful programs have 
shown a median ROI between 2:1 and 3:1. Studies suggest that disease-management 
services account for significantly positive ROI while lifestyle management services 
do not. For example, the partnership between Piedmont and WellStar of Georgia 
supported implementation of care-management programs, with higher quality at 
lower costs. CONCLUSIONS: Although most are not reporting ROI, studies show the 
value of wellness programs should be based on health outcomes.
PHP82
ImPact of clInIcal and HealtH economIc PublIcatIons on 
commercIal success of PHarmaceutIcal Products In tHe u.s
Slejko J.F.1, Basu A.2, Sullivan S.D.3
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Washington, 
Seattle, WA, USA, 3University of Washington School of Pharmacy, Seattle, WA, USA
OBJECTIVES: The study objective was to estimate the causal effect of the publication 
of drug-specific clinical and health economic and outcomes research (HEOR) publica-
tions on US drug product sales. METHODS: Quarterly sales data for twenty-two drugs, 
(biologics for rheumatoid arthritis (RA), new generation asthma drugs and statins) 
and contemporaneous publication counts of HEOR, clinical and meta-analytic stud-
ies via literature search were analyzed. Clinical studies were categorized by journal 
impact factor. The total analysis period spanned 2003-2013, with drug-specific expo-
sure varying based on its branded status over that timeframe. Covariates included 
generic availability, safety warnings, and new indications (as a proxy for sales effort). 
First difference and difference in first difference fixed effects models were used to 
control for unobserved time invariant and constant-rate time-variant unobserved 
confounders and estimate the causal effect of an additional study in a given quarter 
and the increase in sales in the next quarter. RESULTS: In the statin market, the 
potential casual effect of an HEOR study publication on next quarter’s sales was 
$1 - $2.2 million. High-impact clinical publication also significantly increased sales 
in the next quarter (~$7 million). In RA and asthma markets, HEOR studies were not 
statistically linked to quarterly sales, but high-impact clinical studies were found 
to have significant effects on asthma drug sales in the next quarter (~$7.5 million). 
Meta-analyses were only found to have a significant effect on RA drugs sales (~$3.5 
million). CONCLUSIONS: Impact of publications on sales varied. Both HEOR and high-
impact clinical studies were associated with an increase in quarterly sales in the 
statin market, where generic competition is high. These effects were seen to a lesser 
degree in the statin and RA markets, where generic competition is lower. Market 
characteristics that vary across the studied classes, such as branded and generic 
competition, may dictate returns from HEOR and clinical studies.
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OBJECTIVES: Prescription claims databases are used for identifying patients for dis-
ease management programs and studying health outcomes. The growth in the use 
of drug samples and discount generic programs suggests that an increasing number 
of prescriptions dispensed to insured consumers may not be captured on claims 
databases. We examined the extent to which prescription claims databases do not 
provide complete records of insured patients’ drug use and report the top 5 drug 
classes that were dispensed as drug samples and discount generics. METHODS: We 
used the 2012 Medical Expenditure Panel Survey (MEPS) dataset. We included par-
ticipants who purchased at least one prescription medication and had prescription 
drug insurance for 2012. We quantified the extent to which insured patients used 
drug samples and/or discount generics. We reported descriptive statistics. We used 
Enhanced Therapeutic Classification (ETC) codes to report the top 5 drug classes that 
were dispensed as drug samples and discount generics. RESULTS: A total of 78.6% of 
the U.S. non-institutionalized civilian population was insured for prescription drugs. 
Of the total number of prescriptions dispensed to insured consumers, at least 0.5% 
were drug samples and 4.8% were potentially discount generics. Additionally, 8% of 
insured consumers received at least one sample medication and 21.5% used at least 
one potential discount generic product. The top 5 drug classes dispensed as drug 
samples in descending order were statins, Angiotensin Converting Enzyme (ACE) 
inhibitors, beta-blockers (cardiac selective), Selective Serotonin Reuptake Inhibitors 
(SSRIs) and Proton Pump Inhibitors (PPIs). The top 5 drug classes dispensed as dis-
count generics in descending order were statins, ACE inhibitors, SSRIs, beta-blockers 
(cardiac selective) and PPIs. CONCLUSIONS: Our results indicate that drug samples 
do not contribute substantially to the problem of missing prescription data on claims 
databases. A substantial number of prescriptions that are discount generics may be 
missing from these databases.
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OBJECTIVES: While all pharmaceutical organizations are held accountable for dis-
seminating scientific literature supporting their product’s health economics and 
outcomes (HEOR) data, it is not known whether professionals in HEOR agree on the 
quality of materials being disseminated; nor do we know how often these documents 
are developed internally or outsourced. Therefore, the objective of this study was to 
assess the perceived level of quality of the materials as well as who is developing the 
ferent amounts per health category even after adjusting for population size and 
needs. CONCLUSIONS: The cluster analysis indicates that the health areas cannot 
be considered to behave similarly to one another, since there is more than one 
cluster in each year and the clusters are stable over time.
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OBJECTIVES: The objective is to provide data support for government decision-
making by having a general view of the status of disease composition, patient 
flow and use of drug and treatment of inpatients with basic medical insurance in 
cities and towns based on sample survey on the medical service utilization and 
payment of such inpatients from 2010 to 2012. METHODS: Sort all patients by 
the time of being released, according to systematic sampling method, extract a 
certain proportion of the insured patients’ hospitalizing information in sampling 
area. Then project the sample data to the country. Retrospective study using SQL 
server and related software. RESULTS: Total hospitalization expenses under urban 
basic medical insurance increased every year, reaching RMB425.3 billion in 2012, 
got 67.77% increase compared with 2010. Expenses increased primarily due to the 
growth of person-time in receiving treatment. The patient-time in receiving treat-
ment reached 4945 times in 2012, 57.18% increases over 2010. In 2012 the average 
hospitalization expenses amounted to RMB8,601, an increase of 6.75% compared 
with RMB8,057 in 2010. Diseases in circulatory, respiratory, and digestive system 
as well as tumor remain the top four most afflicted, accounting for about 60% of 
the total inpatient population. In the disease sub-category, the three most com-
mon diseases accounted for more than 20% of total diseases in patient-times. 
Due to strengthened clinical management of antibiotics use, expense of systimic 
anti-biotics decreased year by year, with 22.46% in 2012, significantly lower than 
28.99% in 2010. CONCLUSIONS: With the establishment and improvement of 
national health insurance, the needs for medical service of insured patients were 
met with substantive effect, but the resulting pressure on fund spending should 
be given more attention. With the continuous attention to the rational clinical 
treatment, irrationality of clinical medication use has improved, but there still 
remains room to improve.
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OBJECTIVES: This study examines disease-specific spending across the full range 
of conditions to identify which conditions are driving the growth in overall spend-
ing in recent years. METHODS: Truven Health MarketScan data for 8M employees 
and their dependents in FFS plans in 2007 and 12M in 2012 are analyzed. The 
samples were weighted to reflect the demographic composition of all US employer 
health plans in those years (as captured by the US Medical Expenditure Panel 
Survey). Total health care spending for each patient was allocated across diseases 
using the Medical Episode Grouper (MEG). MEG allocates the 16,000 ICD9 diagno-
sis codes into 572 conditions. Drug spending is assigned to conditions based on 
clinical logic. Adjudicated payments were summed for each episode type that a 
patient experienced. Analysis focused on absolute change in level of per member 
per year (PMPY) spending (total and out-of-pocket) from 2007 to 2012. We exam-
ined the contributions of disease prevalence and cost per case. RESULTS: PMPY 
spending grew 3.8% per year between 2007 and 2012. Hospital outpatient spending 
grew faster (5.9%) than other settings and prescription drug spending was lower 
(1.7%). The top 10 conditions account for 32% of all spending growth. Preventive 
health services drove up spending by $73 PMPY and was the number 1 driver of 
increased spending. Deliveries, both vaginal and Cesarean Section were in the top 
10. So too were four conditions where obesity is an aggravating factor. Cost per 
case was much more of growth driver than changes in treated prevalence. 2013 
results will be available for presentation. CONCLUSIONS: Administrative data 
when handled carefully can provide a broad overview of changing healthcare 
landscape. The modest cost growth for this population has been widely shared 
across many conditions.
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OBJECTIVES: The Affordable Care Act (ACA) initiated healthcare reforms that stress 
“triple aim” goals: improving patient care, population health, and reducing costs. 
Hospitals are forming mergers and have expanded their employee health and 
wellness programs. The objectives are to (1) summarize the literature on mergers, 
health outcomes, and cost-containment (2) describe value for money of health and 
wellness programs, and (3) provide examples of successful mergers. METHODS: A 
systematic review was conducted to identify the costs and benefits of mergers and 
wellness programs. Articles after 2008 were compiled using search engines PubMed, 
Galileo, Ebscohost, and Google Scholar. Key terms were “value for money”, “corpo-
rate”, “health and wellness program”, “health plan”, “insurance plan”, “hospital”, 
and “merger.” Exclusion criteria were articles involving forms of consolidation and 
wellness programs not tied to insurance plans and without reported costs and/or 
health outcomes. RESULTS: A total of 29 relevant articles were retrieved. Findings 
revealed mergers prevent hospitals from trading-off quality and services for cost 
reductions. However, studies suggest that anticompetitive effects of mergers will 
increase costs. Before the ACA, employers had wellness programs that were not 
standardized. The ACA encouraged improvement of these programs by funding 
